Viking Thera VKTX

$28.44 -0.22 (-0.77%)

Valuation

Market cap
3,696,863,000
Revenue TTM
$0
Net income TTM
$-359,640,000
P/E (trailing)
0.00
P/E (forward)
—
Profit margin
0.00%
Debt to equity
0.00

Trading

Volume
2,655,300
Avg volume
5,947,090
Day's range
$28.42 – $29.24
Shares out
127,522,000
Stochastic %K
75%
Beta
0.79
Analysts
Strong Buy
Price target
$91.35

Price

Company profile

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as...

Show more

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. The company develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, which is in Phase II clinical trials for metabolic disorders and anemia; VK2735, a novel dual agonist of the glucagon-like peptide 1, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.

Industry
Biotechnology
Sector
Healthcare
Phone
858 704 4660
Website
https://www.vikingtherapeutics.com
Address
9920 Pacific Heights Boulevard, Suite 350, San Diego, United States

Latest news

Stocktwits

VentureBack Nov 11, 10:40 PM
$VKTX NVDA CEO is out we are going to absolutely fly with incoming $$$
0 replies
spodero Nov 11, 10:39 PM
$VKTX Any chance we could convince China to run a honey pot operation at BL?
3 replies
Kylenorth Nov 11, 10:04 PM
$VKTX poor bulls.... starting to lose again
1 replies
Optionking1995 Nov 11, 9:55 PM
$VKTX Every single Fireside Chat is public from today from Stifel Conference. All but one. Viking’s. He cannot cheerlead one bit. He’s obviously short his own company, no?
1 replies
Optionking1995 Nov 11, 9:54 PM
$VKTX BL saw share price go to 45$ on data drop and said “ fuck no, no way am I letting this go up” and proceeds to shaft shareholders all the way back to 24$😂😂😂😂😂 he’s so against his own shareholders it’s sickening!
0 replies
Optionking1995 Nov 11, 9:31 PM
$VKTX would you look at that. Did it again today! Can’t see?
1 replies
Optionking1995 Nov 11, 9:28 PM
$VKTX hmmmm looks just about normal to me! Always 2x down the XBI 😂😂😂😂😂
0 replies
Optionking1995 Nov 11, 9:15 PM
$VKTX guys, keep listening to @biolover. Notice how he isn’t posting as much, or others to that nature that constantly pump the shit out of this company? They are X pumpers who take a wild guess and when they are occasionally right, they take all credit. This is a failure. It will never make it to market and management will have fleeced for Hundreds of Millions of dollars. Save your money, sell this for something else and don’t buy anything. They’ll bring this down to 22 next, and then pump back to 25 then back to 17 and back to 22… Hedge Funds don’t lose money. They short it all the way down and buy back for a pump. Rinse Repeat. This is a PUMP AND DUMP stock that somehow has a couple Billion $ MCAP.
1 replies